Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone added to Ambrisentan in PAH
NCT02253394Phase 4Terminated
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Ambrisentan + Spironolactone with Ambrisentan + Placebo (2 arms). Primary endpoints: Peak Volume of Oxygen Consumption at 90 days and Cardiac Output at 90 days. Started Sep 2015; status: terminated.
02
Drugs
spironolactone
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02253394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253394.